Menu
Cell-free DNA reflects the genetic alterations in the cells they originate from. This is particularly relevant in cancer, where ctDNA (termed circulating tumor DNA) mirrors the genetic mutations of the cancer cells. By analyzing ctDNA, we can gather crucial insights into the cancer’s type, stage, and genetic makeup
Building upon the remarkable work of Prof. Yuval Dor and Prof. Nir Freedman from the Hebrew University of Jerusalem, who developed a technology to identify methylation markers in cfDNA, and cell-free nucleosomes analysis.
DNA methylation is a significant biological process that marks our genetic text, providing critical markers for tissue and cell state derivation. Changes in these methylation patterns can indicate tissue damage, drug toxicity, and malignant transformation.
Our researchers, Drs Zick, Grinspun, and Moss, are applying Prof. Dor’s platform to create monitoring tools for early cancer detection and individualized treatment decisions. By focusing on alterations in nucleosome structure, positioning, and histone modifications, we aim to establish new diagnostic, prognostic, and predictive markers and potentially unveil novel therapeutic targets.
We utilize samples from peripheral blood, urine, and other body fluids to develop this simple cell-free circulating-DNA test, making the testing process minimally invasive and patient-friendly.
At HCRI, we’re committed to maximizing the immense potential of cfDNA and cell-free nucleosomes. Our research is constantly evolving, deepening our understanding of cancer, and progressing towards more precise, personalized, and effective treatments.
By reshaping the future of cancer care with our groundbreaking research, we strive to offer renewed hope to those affected by this disease. At HCRI, we’re not just studying cancer; we’re transforming its future.
Moss J et al: Comprehensive human cell-type methylation atlas reveals origins of circulating cell- free DNA in health and disease. Nat Commun. 2018 Nov 29;9(1):5068
